LEXINGTON, Mass. – BioScale, Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that it has relocated its corporate headquarters to 4 Maguire Road in Lexington, MA. The move will enable BioScale to scale up its commercial, scientific, R&D, and manufacturing functions in the newly renovated 30,000 square foot facility including Biological Level 2 laboratories and a clean room for its MEMs Sensor manufacturing and assembly.

“We’re excited about our new home in Lexington. The positive response we have received from the launch of BioScale’s ViBE product line required us to grow our facility and functionality. We’re building out additional sales, marketing, manufacturing, and application development areas. This growth requires a new, better equipped, and larger facility,” commented Mark Lundstrom, BioScale’s CEO. “The Lexington location, in addition to providing a superior work environment for our employees, is ideally located and will allow BioScale to grow rapidly while simultaneously lowering our cost of operation. It will provide us the facility we need as a home-base for our projected growth in the coming years.”

BioScale’s current staff includes professional, scientific and manufacturing employees. As the company executes its commercialization plans in 2011, significant employee growth is expected through 2012 with many of the roles in supply chain, sales, marketing, manufacturing and operations.

About BioScale

BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE™ platform powered by its AMMP™ (Acoustic Membrane Microparticle) technology enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. BioScale is headquartered in Lexington, MA. For more information, visit www.bioscale.com.

Forward Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding BioScale’s future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company’s ability to obtain financing, the development and commercialization of ViBE systems, the prospects of the Company’s protein analytics platform, the Company’s strategies to develop and commercialize protein analytics systems and the breadth of the Company’s technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. BioScale is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.